Table 1: Summary of MammaPrint risk assessments.

TotalMP high risk (%)MP low risk (%)QNS (%)
Total, unique5433 (61%)7 (13%)14 (26%)
3 LNs positive44 (100%)00

MP indicated tumors*5029 (58%)7 (14%)14 (28%)
1 cm max diameter81 (12%)07 (88%)
 0 positive LNs3419 (56%)4 (12%)11 (32%)
 1–3 positive LNs159 (60%)3 (20%)3 (20%)
 ER+, PR+, HER2+22 (100%)00
 ER−, PR−, HER2+43 (75%)1 (25%)0
 ER+, PR+, HER2−2916 (55%)4 (14%)9 (31%)
 ER−, PR−, HER2−65 (83%)01 (17%)
 ILC41 (25%)03 (75%)
 IDC4628 (61%)7 (15%)11 (24%)
 Caucasian3522 (63%)2 (6%)11 (31%)
 Non-Caucasian157 (47%)5 (33%)3 (20%)
 OncotypeDx low risk93 (33%)2 (22%)4 (44%)
 OncotypeDx intermediate risk53 (60%)02 (40%)

MP: MammaPrint; QNS: quantity not sufficient; LN: lymph node; ER: estrogen receptor status by IHC; PR: progesterone receptor status by IHC; HER2: HER2-neu receptor status by IHC/FISH; ILC: invasive lobular carcinoma; IDC: invasive ductal carcinoma.
*MP indicated in current international guidelines for stage 1 or 2, ER+ or − invasive breast cancer 5 cm in maximum diameter with 3 LNs tumor positive.
One core biopsy specimen was not subsequently assessed for lymph node status.